The current clinical strategies for CRS are guided towards the treatment of the general processes, such as diuretics, to treat volume overload, or angiotensin converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers, mineralocorticoid receptor antagonist or β-adrenergic blockers to inhibit RAAS activation [17,205]. This evidence concerns the gene ACE and congenital rubella syndrome.